Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

At the time, I shared the advice based on the recommendation of a performance coach and several sleep-deprived individuals who had given it a try. I’m happy to report science has now confirmed the ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

The original version of this story appeared in Quanta Magazine. If you want to solve a tricky problem, it often helps to get organized. You might, for example, break the problem into pieces and tackle ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Qiang Tang receives funding from Google via Digital Future Initiative to support the research on this project. Moti Yung works for Google as a distinguished research scientist. Yanan Li is supported ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

As companies like Amazon and Microsoft lay off workers and embrace A.I. coding tools, computer science graduates say they’re struggling to land tech jobs. Manasi Mishra recently graduated from Purdue ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Elizabeth Finkel does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...